If you would like to submit an article for publication in Managed Care, see our Call for papers.
Along with traditional systemic therapies, the American Academy of Dermatology recommends four biologic agents as first-line treatment for psoriasis patients who are candidates for systemic therapy.
Although interactive educational seminars that target physicians require a large investment of resources, they can be cost-effective if medical care is improved as a result.
Sulfonylureas are cost-effective and also may be the only oral agents that inhibit processes inducing hyperglycemia by improving insulin secretion and insulin resistance. New long-acting agents hold even greater promise.
In response to the expense of new migraine therapies, treatment practices aimed at controlling direct costs are now the norm.
Omalizumab, a novel therapy that targets specific steps in the inflammatory cascade of asthma, may benefit the hard-to-treat patient.
New oral treatment options and outcome measures may help patients with type 2 diabetes to achieve better results while reducing associated costs.
Improved outcomes with new biologic agents are prompting physicians to integrate them into therapy for psoriasis patients.
What went wrong between Penn State and Geisinger, and what lessons should be learned?
A relatively new concept in strategic management provides a way to balance quality and customer satisfaction with costs and long-range goals.
; ; ; ;
Continuous subcutaneous terbutaline infusion shows improved clinical outcomes and decreased nursery costs compared with oral tocolytics in women with recurrent preterm labor.